| |
| Device | Sphere-9 Catheter and Affera Ablation System |
| Generic Name | Percutaneous Cardiac Ablation Catheter for Treatment of Atrial Fibrillation with Irreversible Electroporation |
| Applicant | Medtronic, Inc. 8200 Coral Sea St. NE Mounds View, MN 55112 |
| PMA Number | P240013 |
| Date Received | 04/11/2024 |
| Decision Date | 10/24/2024 |
| Product Codes |
OAD OAE QZI |
| Advisory Committee |
Cardiovascular |
| Clinical Trials | NCT05120193
|
| Expedited Review Granted? | No |
| Combination Product | No |
| Predetermined Change Control Plan Authorized | No |
Approval Order Statement approval for the Sphere-9™ Catheter and Affera™ Ablation System. This device is indicated for use in cardiac electrophysiological mapping (stimulation and electrogram recording) and for treatment of drug refractory, recurrent, symptomatic persistent atrial fibrillation (episode duration less than 1 year) and radiofrequency ablation of cavotricuspid isthmus dependent atrial flutter when used with the Affera mapping system. |
| Approval Order | Approval Order |
| Summary | Summary of Safety and Effectiveness |
| Labeling | Labeling
|
| Post-Approval Study | Show Report Schedule and Study Progress |
| Supplements: |
S001 S002 S003 S004 S005 S006 S007 S008 S009 S010 S011 S012 S013 S014 S015 S016 S017 S018 |